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A B S T R A C T   
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections have triggered global pandemic 
that continue to impact adversely human health. New understanding has emerged about the innate and adaptive 
immune responses elicited in SARS-CoV-2 infection. The understanding of innate immune responses generated in 
hosts early in SARS-CoV-2 infection is vital for treatment efforts. Antiviral cytokines are released by innate 
immune cells in response to viral infections that play a pivotal role in limiting viral replication, pathology and 
generating optimal adaptive immune responses alongside the long-term memory responses against reinfections. 
One aspect of innate immune response generated against SARS-CoV-2 in vivo and which has received much 
attention has been high proinflammatory cytokine release in COVID-19 patients. Another vital discovery has 
been that the antiviral cytokine type I Interferon (IFN) family IFN-α mediates upregulation of angiotensin con-
verting enzyme 2 (ACE2) membrane protein in airway epithelial cells. ACE2 is a receptor that SARS-CoV-2 binds 
to infect host cells. New understanding has emerged about the mechanism of SARS-CoV-2 induced exaggerated 
proinflammatory cytokine release as well as transcriptional regulation of ACE2. This review discusses various 
mechanisms underlying SARS-CoV-2 induced exaggerated proinflammatory cytokine response as well as tran-
scriptional regulation of ACE2 receptor. We further elaborate on adaptive and memory responses generated 
against SARS-CoV-2.   
1. Introduction 
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) 
infection is an ongoing global pandemic that has imposed huge burden 
on human health (Zhang and Holmes, 2020; Wu et al., 2020; Corona-
viridae Study Group of the International Committee on Taxonomy of V, 
2020). Intense efforts are being invested to develop new therapeutics 
and more effective vaccines to control the disease. SARS-CoV-2 infection 
causes pneumonia like symptoms including bilateral lung involvement 
followed by acute respiratory distress, and lung damage in advanced 
stages (Lai et al., 2020). SARS-CoV-2 has also been reported to cause 
cardiovascular complications (Tavazzi et al., 2020; Li et al., 2020). A 
significant number of SARS-CoV-2 infected patients develop protective 
immunity even though the nature and duration of protective immunity 
is yet to be fully determined. Excessive levels of proinflammatory cy-
tokines have been detected in COVID-19 patients that function as me-
diators of acute respiratory distress and cardiovascular complications 
such as acute myocarditis and endothelitis (Huang et al., 2020; Ong 
et al., 2020; Zhang et al., 2020a). New knowledge and mechanisms 
leading to proinflammatory cytokine release in SARS-CoV-2 and 
inflammation related damage to lungs and cardiovascular system has 
become available (Tavazzi et al., 2020; Li et al., 2020; Tersalvi et al., 
2020). Involvement of the vascular system in COVID-19 patients could 
be via direct infection of endothelium and driven by inflammatory re-
sponses causing endotheliitis and hypercoagulable state. The ACE2 is a 
cellular receptor for SARS-CoV-2 entry into host. SARS-CoV-2 binds 
ACE2 with high affinity through receptor binding domain (RBD) of 
S-protein (Wrapp et al., 2020; Wan et al., 2020). ACE2 is expressed in 
gastrointestinal tissues, airway epithelium, and on endothelial cells (Bao 
et al., 2020). ACE2 expression in airway epithelial tissues and endo-
thelium represents a major source of SARS-CoV-2 entry into lung 
epithelial tissues and possibly of endothelium potentially leading to 
cardiovascular complications (Imai et al., 2005; Ferrario et al., 2005; 
Varga et al., 2020). This notion is supported by the in vitro data that 
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suggested SARS-CoV-2 could infect engineered human blood vessel 
organoids (Monteil et al., 2020). Patient data further supported virus 
presence within endothelial cells and accumulation of inflammatory 
cells in the heart that could potentially explain the mechanism under-
lying impairment of cardiovascular functions in COVID-19 patients 
(Varga et al., 2020). SARS-CoV-2 entry require S-protein cleavage into 
S1 and S2 by host transmembrane protease, the serine 2 (TMPRSS2) 
protease. S1 binds to the ACE2 receptor whereas S2 activity is required 
to form membrane fusion with the host cells (Ziegler et al., 2020). The 
TMPRSS2 protease has also been associated with gender related mor-
tality differences observed between males and females infected with 
SARS-CoV-2 with reports indicating increased prevalence of COVID-19 
cases in males compared with females (Mjaess et al., 2020; Jin et al., 
2020). This effect could be related to coregulation of androgen hormone 
receptor and TMPRSS2 gene in what is described as 
TMPRSS2-androgens axis. The TMPRSS2 gene expression is regulated by 
androgen receptors (Lin et al., 1999). Androgen receptor gene is located 
in close proximity with TMPRSS2 locus (Shen et al., 2017). 
Model organisms could help investigate the mechanisms related to 
cardiac and lung injury associated with SARS-CoV-2. The K18-hACE2 
transgenic mouse model generated by Jackson Laboratories could be 
one such useful resource for studying SARS-CoV-2 pathogenesis. K18- 
hACE2 transgenic mice expresses human ACE2-coding sequences 
under transcriptional regulation of human cytokeratin K18 promoter 
driving ACE2 expression predominantly in epithelial cells. Thus, 
allowing SARS-CoV-2 to bind lung epithelium and potentially gener-
ating respiratory distress resembling human COVID-19 severe acute 
respiratory syndrome, which is responsible for majority of hospitaliza-
tion and disease related deaths. Boa et al; created a new hACE2 trans-
genic mouse model (Bao et al., 2020). This model was tested for 
SARS-CoV-2 pathogenicity. SARS-CoV-2 was delivered intranasally and 
following the disease progression histopathological examination was 
performed that revealed interstitial pneumonia and lung damage. The 
lung infiltrates appear to have accumulation of lymphocytes and alve-
olar macrophages suggesting a possible lung damage due to excessive 
proinflammatory cytokine response and macrophage activation (Bao 
et al., 2020). The study does not examine in detail the involvement of 
TLRs and cytokine release from innate immune cells. One drawback with 
hACE2 transgenic mice model is that it cannot reliably recapitulate 
human innate and adaptive responses elicited against SARS-CoV-2. 
Therefore, a humanized mouse model expressing human airway 
epithelial tissues and human immune system may be a reliable model. 
The Lung only Mice (LoM) model may be one such model. The LoM 
model was created by implanting human lung tissues on an immuno-
deficient background. However, this mouse model lacks an immune 
system. Alternatively, the BLT-L (bone marrow, liver, thymus and lung 
tissue) which is a humanized mouse model that can generate hemato-
poietic system from transplanted bone marrow. The BLT-L humanized 
mouse model was created by the same group that developed the 
Lung-only Mice. In BLT-L model the autologous bone marrow, liver, 
thymus tissue, and lung tissue are engrafted on an immunodeficient 
background. The benefit of BLT-L model over LoM is that this model can 
generate innate and adaptive responses against viral infections (Wahl 
et al., 2019), thus, could serve as a model to investigate human immune 
responses against SARS-CoV-2 infection. 
A crosstalk between innate and adaptive immune responses is 
essential for eradicating SARS-CoV-2 infection as well as for generating 
long term memory responses against reinfections. There is little under-
standing about the innate and adaptive immune responses elicited in 
SARS-CoV-2 infections in vivo in humans and in animal models. This 
review in below sections construct an innate and adaptive immune 
response model based on the recently published data on SARS-CoV-2 
pathogenesis and immune responses measured in COVID-19 patients. 
2. Cellular receptors sensing SARS-CoV-2 
2.1. Viral associated molecular patterns 
Innate immune responses against viral infections are elicited after 
host innate immune cells through their pattern recognition receptors 
(PRRs) recognize virus associated molecular patterns. Viruses utilize 
coat/membrane proteins to enter host cells by binding specifically on 
receptors/coreceptors. Host cells respond by internalizing viruses 
through receptor mediated endocytosis (Mercer et al., 2010). A second 
mechanism involves viruses attaching and aggregating non-specifically 
on host cell membranes e.g., cell membrane polysaccharides triggering 
clathrin mediated endocytosis or other less characterized endocytosis 
mechanisms such as micropinocytosis or caveolar dependent endocy-
tosis (Mercer et al., 2010; Gruenberg, 2001). Once inside the host cells, 
internalized viruses are delivered to endosomes. Endosomes have low 
pH and are rich in proteases that among others include the cathepsins, 
their activity leads to uncoating of viruses and subsequent penetration 
into cytoplasm (Chandran et al., 2005). No direct evidence exists yet of 
SARS-CoV-2 engaging endosomal pathway. However, based on other 
CoV families such as SARS-CoV and Middle Eastern Respiratory Syn-
drome (MERS-CoV), which have been shown to engage the endocytic 
pathways (Yang and Shen, 2020; Wang et al., 2008; Qing et al., 2020; 
Simmons et al., 2005). It is most likely, therefore, that SASR-CoV-2 may 
be also engaging receptor mediated endocytosis, which is being explored 
as a potential therapeutic target to control SARS-CoV-2 infection and 
COVID-19 (Yang and Shen, 2020). 
Endosomes are rich in endosomal toll-like receptors (TLRs) which 
sense viral genomes. The retinoic acid-inducible gene-I (RIG1) like re-
ceptors (RLRs) are second class of intracellular receptors that sense viral 
genomes after their penetration into cytoplasm. Innate immune cells as 
well as epithelial cell surfaces form the first line of defense against 
pathogens, they express both TLRs and RLRs (Akira et al., 2006). The 
endosomal TLR3 detects viral double-stranded RNA (ds-RNA) genome, 
which is transient replication intermediate of single stranded RNA 
(ss-RNA) viruses (Alexopoulou et al., 2001). Likewise, endosomal TLR7 
and TLR8 detect viral ss-RNA (Diebold et al., 2004). Currently, it is not 
clear if endosomal TLRs or RLRs or both sense SARS-CoV-2 genome. 
SARS-CoV-2 contain RNA genome therefore involvement of both classes 
of receptors in sensing SARS-CoV-2 genome cannot be ruled out. 
2.1.1. Mechanism of SARS-CoV-2 recognition by host pattern recognition 
receptors 
The mechanism driving exaggerated proinflammatory cytokine 
response and deleterious T cell activity in COVID-19 patients is presently 
unclear (Ong et al., 2020; Zhou et al., 2020). The data discussed above 
suggest a potential involvement of Interferon regulatory factors that 
become activated through TLRs or RLRs mediated signaling pathways. 
No direct evidence exists yet that demonstrates SARS-CoV-2 structural 
proteins binding to any of the transmembrane TLRs, however, the likely 
candidates may be TLR2 or TLR4 as these have already been shown to 
engage viral coat proteins (Fig. 1). The herpes simplex virus 1 (HSV-1) 
and respiratory syncytial virus (RSV) envelope proteins have been 
shown to bind TLR2 and TLR4 triggering proinflammatory cytokine 
release (Kurt-Jones et al., 2004, 2000). A recent study demonstrated 
increased TLR2 mRNA fold expression in mild/moderate COVID-19 
patients compared with healthy controls (Hadjadj et al., 2020). Simi-
larly, the viral ds-RNA genomes bind to endosomal TLR3 whereas viral 
ss-RNA genomes bind to TLR7 and TLR8 (Akira et al., 2006; Alex-
opoulou et al., 2001; Diebold et al., 2004; Heil et al., 2004). Therefore, it 
may be anticipated that TLR7/8 could sense the SARS-CoV-2 genome 
(Fig. 1). However, no direct evidence exists showing SARS-CoV-2 
genome binding to TLR7/8. Even the data related to TLRs sensing 
RNA genomes of SARS family viruses e.g., SARS-CoV and MERS-CoV is 
not clear with the exception that TLR adaptor MyD88 and TRIF were 
shown to be important for innate antiviral immunity in mouse models 
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(Totura et al., 2015). Hadjadj et al., in recently published article 
demonstrated an increased expression of TLR7 in mild/moderate 
COVID-19 patients compared with healthy controls, whereas TLR8 
expression was also elevated in severely ill COVID-19 patients compared 
with mild/moderate cases (Hadjadj et al., 2020). Interestingly, in the 
paper the interferon gene expression heatmap analysis revealed that 
IRF5 and IRF7 expression to be low in healthy controls as expected 
whereas their expression increased strongly in mild/moderate and 
severely ill COVID-19 patients followed by abrupt decrease in critically 
ill patients (Hadjadj et al., 2020). The kinetics of IRF5, IRF7 expression 
data could potentially explain the mechanism underlying reduced levels 
of type I and III interferon detection in severely ill COVID-19 patients 
(Trouillet-Assant et al., 2020; Gardinassi et al., 2020). 
2.1.2. Involvement of TLR mediated signaling pathways in SARS-CoV-2 
infection 
The sensing of SARS-CoV-2 ss-RNA genome is anticipated to activate 
TLR7/8-MyD88-TRAF6-IRF5/IRF7 or TLR7/8-MyD88-IKK-NF-κB 
signaling pathways (Fig. 1 (Akira et al., 2006; Diebold et al., 2004; 
Honda et al., 2004)). Hadjadj et al., publication predicted the involve-
ment of NF-κB signaling pathway especially in relation with its tran-
scriptional regulation of IL6 and TNFα (Hadjadj et al., 2020). The role of 
intracellular RLRs such as MDA5, RIG1 sensing SARS-CoV-2 viral 
genome is actively being investigated. It may be anticipated that after 
sensing viral genome by MDA5 or RIG1 that signal via caspase activation 
and recruitment domain (CARD) bind to mitochondrial MAVS protein. 
MAVS recruit TRAF3-TRADD-RIP1 activating IKK complex that in turn 
activate NF-κB, IRF3 and IRF7 transcription factors (Fig. 1 (Yoneyama 
et al., 2004; Honda et al., 2005)). Therefore, we expect the above 
described signaling pathways to be activated in innate immune cells 
sensing SARS-CoV-2 thereby leading to synthesis of proinflammatory 
cytokines and IFNs. IFNs subsequently mediate antiviral protein syn-
thesis in infected host epithelial cells. The activated innate immune cells 
release type I IFN that bind to IFNA-R activating JAK-STAT signaling 
pathway inducing transcription of antiviral proteins as well as ACE2 
receptor upregulation as predicted in the model (Ziegler et al., 2020). 
Earlier studies on SARS-CoV have indicated that SARS-CoV accessory 
open reading frame 6 (ORF6) could antagonize interferon responses by 
inhibiting STAT1 nuclear localization (Frieman et al., 2007; Kopeck-
y-Bromberg et al., 2007). Similarly, SARS-CoV-2 ORF6 (which shares 
~66 % sequence homology with SARS-CoV ORF6) have been reported to 
be involved in suppressing IFN production potentially through inhibi-
tion of IRF3 and STAT1 nuclear localization in a mechanism that seem to 
be independent of STAT1 phosphorylation (Lei et al., 2020). Coronavi-
rus families use proteases to cleave replicase proteins. Novel SARS-CoV 
gene 1 product encodes replicase polypeptide that is processed into 
Fig. 1. Predicted model depicting innate 
immune responses against SARS-CoV-2. 
SARS-CoV-2 enters epithelial/endothelial cells 
utilizing ACE2 receptor. The viral genome and 
surface proteins are sensed by TLRs and RIG like 
receptor family present in tissue resident and 
migratory dendritic cells triggering inflamma-
tory and chemokine responses. Proin-
flammatory cytokines have been detected in 
COVID-19 patients suggesting SARS-CoV-2 sur-
face proteins may be potentially recognized by 
TLR4 or TLR2 activating MyD88→TRAF6-IRAK. 
This assumption is based on studies showing 
HIV, HSV viral structural proteins binding to 
TLR2 (Henrick et al., 2015; Leoni et al., 2012) 
as well as recent RNA-sequencing data in 
COVID-19 patients (Hadjadj et al., 2020). The 
TRAF6 functions as E3 ligase to ubiquitinate 
IRF7 as well as NEMO of IKK complex. Ubiq-
uitinated IRF7 also becomes phosphorylated, 
dimerize, and translocate into the nucleus to 
initiate transcription of antiviral cytokines. The 
IKKβ kinase of IKK complex phosphorylate IκBα 
of NF-κB releasing p65/p50 that enter the nu-
cleus initiating proinflammatory cytokine gene 
transcription program. Likewise, SARS-CoV-2 
genome binding to TLR7 or TLR8 activates 
MyD88→TRAF6-IRAK complex. The TLR7 and 
TLR8 have been found to be expressed in 
mild/moderate and severely ill COVID-19 pa-
tients respectively (Hadjadj et al., 2020). The 
TRAF6 ligase ubiquitinates IRF5. The IRF5 un-
dergo phosphorylation, dimerize, and trans-
locate into nucleus to transcribe 
proinflammatory cytokines, type I IFN e.g., 
IFNα/β. SARS-CoV-2 could bind to TLR3, MDA5 
or RIG1 helicases during its replication wherein 
it generates a transient double stranded RNA 
structure. The dsRNA binding to TLR3 recruits TRIF adaptor to activate IRF3. Likewise, the dsRNA binding to RIG1 could activate IFN gene transcription via IRF7. 
The IFN-α/β has been shown to upregulate ACE2 receptor in airway epithelial cells. The IFN-α/β bind to IFNA receptor. The binding leads to IFNA receptor 
dimerization and ITAM phosphorylation to serve as a docking site for JAK receptor tyrosine kinases that become activated through autophosphorylation within 
tyrosine residues. The activated JAKs phosphorylate STATs leading to their dimerization and nuclear translocation. STAT dimers activate antiviral gene transcription 
program some of which are involved in cleaving viral proteins and viral RNAs in infected cells. STAT dimers also potentially bind to the ACE2 upregulating its 
expression. Interferon regulatory factors IRF7, IRF5, IRF3 and NF-κB including elements of interferon and STAT signaling pathways have been detected in peripheral 
lymphocytes (Wilk et al., 2020) and immune cells present in bronchoalveolar lavage of COVID-19 patients (Liao et al., 2020).   
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nonstructural proteins (NSPs) through activity of two proteases among 
which include papain-like protease (PLpro) (Harcourt et al., 2004). 
PLpro is an essential component of protease machinery in SARS-CoV-2. 
Its activity is involved in evasion of innate antiviral responses through 
cleavage of ubiquitin-like interferon-stimulated gene 15 (ISG15) protein 
linked with IRF3 as well as partial deubiquitination especially K48-Ub2 
of other substrates in vitro. Cleavage of ISG15 posttranslational modifi-
cation of IRF3 contributed to reduced type I IFN production whereas 
inhibiting PLpro promote TBK-IRF3 pathway demonstrating utility of 
targeting negative regulators of IFN pathway for control of SARS-CoV-2 
and COVID-19 (Shin et al., 2020). Liu et al., recently demonstrated that 
SARS-CoV-2 papain-like protease mediate de-ISGylation of melanoma 
differentiation antigen (MDA5), which senses coronavirus RNA genome 
(Menachery et al., 2014; Liu et al., 2021). The de-ISGylation of MDA5 
allows escape of SARS-CoV-2 sensing and antiviral responses (Liu et al., 
2021). 
The antiviral transcription factor IRF5 has been recognized to be 
involved in transcriptional upregulation of proinflammatory cytokines, 
chemokines, and type I IFNs especially IFNα4, IFN-β in response to 
TLR7/8 recognizing single stranded RNA viruses in vivo e.g., influenza A 
virus, murine norovirus, West Nile Virus, Newcastle disease virus 
(Graham et al., 2007; Forbester et al., 2020; Barnes et al., 2004). IRF5 is 
also associated with systemic lupus erythematosus (SLE), an autoim-
mune disease characterized by highly elevated type I IFN in patient 
serum (Graham et al., 2007; Eames et al., 2016). Both human and mouse 
IRF5 undergo Lys-63 ubiquitination in vitro in response to sensing 
TLR7/8 agonist R848 (resiquimod), a potent innate immune cell acti-
vator (Balkhi et al., 2008). K63-ubiquitination of IRF5 has been reported 
to be vital for its stability, nuclear translocation, recruitment to virus 
response elements present in proinflammatory and type I IFN genes 
(Balkhi et al., 2008; Paun et al., 2008). IRF5 becomes activated via the 
MyD88-TRAF6-IRAK pathway. TRAF6 is the E3-Ligase that catalyses 
K63-ubiquitination of IRF5 (Balkhi et al., 2008). Correspondingly, the 
serum collected from mice infected with NDV virus or plasmacytoid 
dendritic cells deficient in IRF5 were shown to produce reduced 
amounts of proinflammatory cytokines and type I IFNs (Paun et al., 
2008; Takaoka et al., 2005). IRF7 is another transcription factor which is 
vital for antiviral innate and adaptive immunity. IRF7 becomes 
K63-ubiquitinated in MyD88-TRAF6 pathway in response to TLR7/8 
sensing viral single strand RNA genomes. Abrogating 
K63-ubiquitination inhibits type I IFN transcription (Honda et al., 2005; 
Kawai et al., 2004). Interestingly, the early response IFNα4 which is 
regulated by IRF5 in positive feedback mechanisms activates delayed 
IFN genes as well as IRF7 (Marie et al., 1998). The role of IRF5 and IRF7 
and the mechanism of their activation through ubiquitination or phos-
phorylation during SARS-CoV-2 infection is unknown. Furthermore, it is 
also unknown if these two vital anti-viral regulatory factors are involved 
in regulating transcription of excessive proinflammatory cytokines in 
response to SARS-CoV-2 infection (Fig. 1). Recent reports using single 
cell RNA sequencing performed on peripheral blood mononuclear cells 
of COVID-19 patients compared to healthy controls revealed elements of 
interferon signaling pathways, IRF7, IRF5, IRF3 to be highly elevated 
suggesting their potential role in generating interferon responses (Wilk 
et al., 2020). Likewise, the bronchoalveolar lavage immune cell profiling 
using single cell RNA sequencing also revealed an enrichment of 
expression clusters consistent with activation of innate immune cells and 
interferon-STAT signaling pathways as elaborated in above sections 
(Liao et al., 2020). In a study performed by Zhang et al., loss of function 
variant alleles was detected in COVID-19 patients presenting life 
threatening pneumonia. The loss of functional allele variants correspond 
to TLR and IFN genes including autosomal-recessive deficiencies of IRF7 
and IFNAR1 and autosomal-dominant deficiencies of TLR3, UNC93B1, 
TICAM1, TBK1, IRF3, IRF7, IFNAR1, and IFNAR2 (Zhang et al., 2020b). 
In the same study, Zhang et al., further demonstrated that IRF7 deficient 
plasmacytoid dendritic cells were refractory to IFN production upon 
SASR-CoV-2 infection lending credibility to the model presented in 
Fig. 1. Taken together, elucidating the role of IRF3, IRF5, IRF7, and 
mechanisms of their activation can prove vital for our understanding of 
innate immune responses elicited against SARS-CoV-2 infection. As 
additional evidence begins to emerge, their role is also becoming more 
clearer especially related to excessive proinflammatory cytokine release 
and perturbation of type I interferon production during progression of 
SARS-CoV-2 infection from moderate to severely ill stages (Lei et al., 
2020). Correspondingly, whether NF-κB, IRF5 could serve as drug tar-
gets in controlling excessive IL6 release in COVID-19 patients’ needed to 
be investigated. There is also a potential for enhancing activity of IRF7, 
IRF3 to promote type I IFN production (Shin et al., 2020; Zhang et al., 
2020b). Even though the clinical relevance of these factors in controlling 
SARS-CoV-2 and for generating protective immunity in COVID-19 re-
mains unknown. Synagren, the respiratory drug discovery and devel-
opment company in June 2020 released a report on a phase II trial 
performed with its experimental drug SNG001 in COVID-19 patients 
(NCT04385095). SNG001 is an IFN-β inhalation drug with reports of 
benefit in COVID-19 patients (https://www.synairgen.com). 
2.1.3. Interferon and inflammatory responses in SARS-CoV-2 infection 
Some of the earlier studies performed on COVID-19 patients utilized 
plasma samples or RNA extracted from whole blood to examine cytokine 
profile and gene expression. These studies revealed elevated levels of 
proinflammatory cytokines in patient serum such as IL-6, IL8, IL1α, IL1β, 
TNFα, as well as type I interferon, IFN-α/β (Huang et al., 2020; Ong 
et al., 2020). However, the data presented in these two publications 
lacked quantitation, it was not clear how high the IFN-α/β levels were 
present in COVID-19 patients. It is interesting to note that excessive 
proinflammatory cytokines have also been reported in SARS-CoV and 
MERS-CoV infections (Peiris et al., 2003; Drosten et al., 2003). Despite 
IFN response in lung tissues there is no definitive proof yet of systemic 
IFN response in COVID-19 patients (Trouillet-Assant et al., 2020; Gar-
dinassi et al., 2020; Zhang et al., 2020c; Song et al., 2020). A study by 
Blanco-Melo D et al., detected only low levels of type I and III interferon 
whereas higher levels of chemokines and IL6 were detected in primary 
human bronchial epithelial cells in vitro, ferret animal model, and in 
serum of SARS-CoV-2 infected patients (Blanco-Melo et al., 2020). In 
another study by Hadjadj J, et al., no IFN-α/β were detected in severely 
ill COVID-19 patients whereas elevated levels of IL6 and TNFα could be 
detected (Hadjadj et al., 2020). Several other publications have also 
reported of detecting only low levels of type I and III IFNs in peripheral 
lymphocytes and in plasma of COVID-19 patients whereas IL6, C-reac-
tive protein (CRP), and chemokine IFNγ–induced protein 10 (IP-10) 
could be detected at higher levels (Trouillet-Assant et al., 2020; Gardi-
nassi et al., 2020). The serum cytokine levels in COVID-19 patients can 
show age dependent variation. For examples, in children and young 
adults <24 years of age Interleukin 17A and IFN-γ were detected to be 
high however their levels dropped significantly in older patients (>24 
years) (Tang et al., 2008). The persistently elevated levels of serum IL1 
and IL6 in COVID-19 patients resemble macrophage activation syn-
drome (MAS)/hemophagocytic lymphohistiocytosis (HLH) (Tang et al., 
2008). Two types of HLH have been described, the primary and sec-
ondary. A rare autosomal recessive trait causes primary HLH in children 
whereas secondary HLH/MAS may be driven by infections or autoim-
mune diseases (Risma and Jordan, 2012; Barrett et al., 2014). HLH/MAS 
is characterized by histiocytes infiltration of vital organs and abnormal 
immune activation as well excessive proinflammatory cytokine presence 
in serum (Barrett et al., 2014; Grupp et al., 2013). COVID-19 patients 
who present with acute respiratory distress syndrome (ARDS) have been 
shown to respond to anti-IL-6R blockade with tocilizumab (Yao et al., 
2020; Giamarellos-Bourboulis et al., 2020). Tocilizumab is standard 
therapy applied to reverse clinical symptoms associated with Cytokine 
storm syndrome (CRS) in patients who receive autologous chimeric 
antigen receptor (CAR) modified T cells (Grupp et al., 2013; Davila et al., 
2014). 
Multisystem Inflammatory syndrome in children. Some children 
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with COVID-19 present multiorgan inflammation referred to as Multi-
system Inflammatory syndrome in children (MIS-C) associated with 
SARS-CoV-2 (Harwood et al., 2020; Godfred-Cato et al., 2020). The 
disorder presents clinical features characterized by shock, macrophage 
activation, and Kawasaki like disease. Kawasaki is a rare acute disease 
characterized by vasculitis affecting small and medium size arteries, 
some present with long-term effect on coronary arteries leading to 
coronary artery dilation or aneurysms (Kato et al., 1996; Verdoni et al., 
2020). The median age of children with MIS-C is ~8 years. Such children 
present with multiorgan inflammation in gastrointestinal, cardiovascu-
lar, respiratory, hematologic and mucocutaneous tissues (Feldstein 
et al., 2020; Jiang et al., 2020; Dufort et al., 2020). The elevated serum 
cytokines especially IL1 and IL6 and other proinflammatory cytokines 
detected in COVID-19 patients suggest an early innate immune response 
elicited against SARS-CoV-2 infection potentially involves TLR mediated 
recognition of viral PAMPs (Zhang et al., 2020b). The TLRs recognizing 
SARS-CoV-2 PAMPs can be present on alveolar macrophages, tissue 
resident dendritic cells (DC’s) and DC’s in blood (Ong et al., 2020; 
Yoshikawa et al., 2009). The data further imply that nasal epithelial 
cells, innate immune cells especially conventional dendritic cells (cDCs), 
and alveolar macrophages may shape the early adaptive immune re-
sponses in COVID-19 patients. It also appears from the study that 
attenuated T cell response leads to prolong survival of COVID-19 pa-
tients whereas strong T cell response induced lung damage (Ong et al., 
2020). The deleterious T cell and proinflammatory cytokine responses in 
some COVID-19 patients could be triggered by exaggerated proin-
flammatory cytokine production involving activity of IRF3, IRF5, IRF7, 
and others (Ong et al., 2020). IRF3 and IRF7 being the key regulatory 
factors involved in type I IFN gene transcription. IFN-α/β promotes 
upregulation of MHC Class I molecules which is important for CD8 
mediated adaptive immune responses (Matsuyama et al., 1993; Tani-
guchi et al., 2001). It is possible that interferon regulatory factors may 
also be involved in regulating SARS-CoV-2 viral antigen presentation 
and, thus, shaping adaptive immune responses. 
3. Adaptive immune responses in SARS-CoV-2 
3.1. Autoantibodies and B cell responses in COVID-19 patients 
Autoantibodies against interferons have been detected in severely ill 
COVID-19 patients presenting pneumonia. The IgG autoantibodies were 
detected against IFN-ω and IFN-α2. Correspondingly, in the in vitro 
studies these autoantibodies neutralized IFN-ω, IFN-α2. These data 
support the protective role of IFNs against SARS-CoV-2 pathogenesis in a 
subset of patients (Bastard et al., 2020). The exact mechanism under-
lying B cell responses against SARS-CoV-2 in vivo is presently unclear. 
The professional dendritic cells and helper T cells orchestrate B cell 
responses. Soluble viral antigens or antigens dragged into lymph nodes 
by migratory APCs can crosslink BCRs to activate antibody mediated 
responses, the fixation of complemet pathways, and memory B cell 
development (Wykes et al., 1998). For B cell responses CD4 T cell help is 
vital. The CD4 T cell responses in SARS-CoV-2 were correlated with 
protective IgG and IgA antibody titers confirming T cell dependent B cell 
responses in COVID-19 patients (Grifoni et al., 2020a). Since the CD4 T 
cell responses in SARS-CoV-2 appeared to be TH1, it is essential to 
examine cytokine profiles to confirm the role of other T helper subtypes. 
The predicted T cell responses generated against SARS-CoV-2 infections 
in vivo has been represented as a model (Fig. 2). Several elements of the 
model have been revealed recently. The nature of CD4 and CD8 T cells 
responding to SARS-CoV-2 infection appeared to be conventional 
effector T cells capable of generating robust T helper and memory re-
sponses against reinfections (Dan et al., 2021; Grifoni et al., 2020b; 
Suthar et al., 2020) (Fig. 2). Dan et al., demonstrated memory B cells, 
antigen specific CD4 and CD8 T cells persist ~8 months post 
SARS-CoV-2 infection. SARS-CoV-2 S-protein, RBD specific anti-IgG ti-
ters that correlated with neutralizing responses (Suthar et al., 2020), and 
anti-IgA antibodies could be detected ~6 to 8 months post infection. 
Likewise, memory B cells expressing IgG isotype showed similar pattern 
of persistence. SARS-CoV-2 protein specific CD4 and CD8 T memory 
cells were also detected, however, in contrast with memory B cells, their 
number declined ~50 % within 6–8 months (Dan et al., 2021), which is 
not unprecedented. A study by Gaebler et al., also demonstrated RBD 
specific IgG and IgM presence in SARS-CoV-2 infected individuals that 
decreased significantly, however, the neutralizing antibody decreased 
Fig. 2. A predicted model depicting T cell 
responses againstSARS-CoV-2 infection. The 
model depicts CD8 T cells (A) and CD4 T cells 
(B) responses in SARS-CoV-2 infection. The 
CCR7+ migratory dendritic cells present exog-
enously acquired and processed SARS-CoV-2 
antigens to CD8 T cells via cross presentation 
or to CD4 T cells via canonical presentation in 
tissues and lymph nodes. Tissue resident alve-
olar macrophages (TRAMs) also become infec-
ted with SARS-CoV-2, thus, can present 
endogenously processed viral antigens to CD8 T 
cells. Antigen reactive CD4 and CD8 T cells 
differentiate into effector T cells. With the 
elimination of infections effector T cells differ-
entiate into terminal effector T cells followed by 
their contraction generating alongside long 
lived memory T cells. The phenotype of mem-
ory precursors and their ability to generate 
recall responses against SARS-CoV-2 reinfection 
is presently unclear. Activated CD4 T cells 
release effector cytokines that help B cells re-
sponses. CD8 T cells appear to follow a linear 
differentiation program in COVID-19 patients 
(Wilk et al., 2020).   
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only by ~5 fold whereas RBD specific memory B cells persist around 
~6-months (Gaebler et al., 2021). Interestingly, apart from humans, the 
IgG antibody adoptive transfer from convalescent SARS-CoV-2 rhesus 
macaques provided protection to naive rhesus macaques upon challenge 
with SARS-CoV-2 (McMahan et al., 2021). These studies demonstrated a 
robust elicitation of both humoral and T cells mediated effector and 
memory responses against SARS-CoV-2 that persist and, thus, can pro-
vide long-term protection against reinfections. 
3.1.1. Innate and adaptive immune system interact in SARS-CoV-2 
infection 
The mechanism of antigen specific T cell differentiation into effector 
and memory precursors in SARS-CoV-2 infection is poorly understood. 
In acute viral infections, the naïve/resting CD8 T cells become activated 
after interacting with professional antigen presenting cells that present 
viral antigens via canonical endogenous pathway or non-canonical cross 
presentation in tissues and draining lymph nodes. The activated T cells 
react and eliminate virally infected tissues (Gerlach et al., 2013; 
Kakaradov et al., 2017). With the elimination of acute infections, ma-
jority of antigen reactive effector T cells become programmed to 
terminally differentiate and undergo apoptosis where as a small per-
centage of cells survive that differentiate along memory T cell lineage 
(Balkhi, 2020). CD4 helper T cells via cytokine secretion play a vital role 
in B cell survival and antibody class switch recombination as well as CD8 
memory T cell generation (Ahmed and Gray, 1996; Sun and Bevan, 
2003). The interaction between innate and adaptive immune system in 
SARS-CoV-2 infection has recently been revealed. A landmark study by 
Grant et al., examined cross talk between innate and adaptive T cells in 
SARS-CoV-2 infected severely ill patients who have developed pneu-
monia. The RNA-seq data demonstrated enrichment of CD4 T cells, CD8 
T cells, monocytes, CCR7+ migratory dendritic cells present in alveolar 
spaces, and TRAMs (tissue resident alveolar macrophages). Through 
single cell RNA-seq analysis, Grant et al., further demonstrated 
SARS-CoV-2 infection of alveolar macrophages (Grant et al., 2021). 
Additional evidence obtained through RNA sequencing analysis per-
formed on peripheral lymphocytes and bronchoalveolar infiltrates 
indicated robust generation of SARS-CoV-2 specific effector CD8 T cell 
responses in moderately ill COVID-19 patients. The effector CD8 T cell 
response seem to decline in severely ill patients (Liao et al., 2020). 
Despite some of these recent findings, lack of suitable animal model 
remains a major bottleneck that hampers complete understanding of T 
cells responses generated against SARS-CoV-2 in vivo. Nevertheless, 
several pieces of data have been published on human MERS-CoV, 
SARS-CoV infections in humans and non-human primates that 
revealed robust T cell responses. The MERS-CoV specific CD4 and CD8 T 
cells were detected in patients exposed to MERS-CoV as well as patients 
that recovered from the disease. Using MERS-CoV specific 20-mer pep-
tide corresponding to viral structural components i.e., surface, spike (S), 
membrane (M), and envelope (E) proteins, both CD4 and CD8 T cells 
could be detected in MERS-CoV infected patients indicating generation 
of both T helper and antiviral cytotoxic T cell responses (Alshukairi 
et al., 2018; Zhao et al., 2017). Remarkably, apart from effector T cells, 
both CD8 and CD4 T cell effector memory (CD45RA− ) population were 
detected in MERS-CoV survivors indicating generation of effector 
memory T cell responses (Zhao et al., 2017). An excellent study pub-
lished recently demonstrated SARS-CoV-2 specific T cell responses in 
COVID-19 convalescent patients. The study utilized an In silico pre-
dicted SARS-CoV-2 HLA I and II peptides designed to be recognized by 
antigen activated CD4 and CD8 TCRs (Grifoni et al., 2020a; Have-
nar-Daughton et al., 2016). In the same study, CD4 T cell recognition of 
SARS-CoV-2 S-protein specific peptides were detected to be more robust. 
CD4 T cell responses are vital for vaccine efforts and the results are 
important because S-protein is explored as the dominant epitope for 
vaccine -development against SARS-CoV-2 (Grifoni et al., 2020a; Gray 
et al., 2018). Activated CD4 T cells release cytokines especially IL4, IL5, 
IL2, IFNγ, TNFα that play vital role in antibody class switch 
recombination, CD8 T cells activation, memory generation, and matu-
rations of professional dendritic cells (Fig. 2, (Sun and Bevan, 2003; 
Banchereau and Steinman, 1998; Bennett et al., 1998; Leist et al., 
1989)). 
4. Concluding remarks 
Several new resources have been developed recently that can help 
investigate the immune responses elicited against SARS-CoV-2 in vivo in 
the mouse and cell line models. The heat-inactivated SARS-CoV-2 (ATCC 
VR-1986HK), total SARS-CoV-2 RNA genome (ATCC VR-740D), and 
SARS-CoV-2 expression vectors (Addgene) can be utilized to identify 
cellular pattern recognition receptors sensing SARS-CoV-2 associated 
molecular patterns as well as elucidating signaling pathways involved in 
synthesis of proinflammatory cytokines, type I interferons, and antiviral 
proteins. Furthermore, these resources can help explore the additional 
mechanisms underlying regulation of ACE2 in airway epithelial cells as 
well as transcriptional regulation of protease TMPRSS2. 
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